Therapy may be instituted before the results of the caltures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.

1. Cryptococcosis, including cryptococcal meningitis and infestions of other sides (e.g., pulmonary, cutaneous). Normal hosts and patients with AIDS, organ transplants or other causes of immunosuppression maybe treated. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.

2. Systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidal infections. These include infections of the peritoneum, endocardium, eye, and pulmonary and urinary tracts. Patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated.

3. Mucosal candidiasis. These include oropharyngeal, esophageal, non-invasive broncopulmonary infections, candiduria, mucocutaneous and chronic oral atropic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function maybe treated. Prevention of relapse of oropharyngeal candidiasis in patients with AIDS.

4.Genital candidiasis. Vaginal candidiasis acute or recurrent; and propylaxis to reduce the incidence of recurrent vaginal candidiasis (3 or more episodes a year). Candidal balanitis.

5.Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy.

6.Dermatomycosis including tinea pedis, tinea corpuris, tinea cruris, tinea versicolor, and dermal candida infections.